Evandro de Azambuja: Real-World Evidence Supporting APT Strategy in HER2+ Breast Cancer
Evandro de Azambuja, BSMO President 2023-2026, shared a post on LinkedIn:
“RWE evidence supports the de-escalation APT strategy for stage I HER2+ early breast cancer.
The 5-year rwDFS rate was 95.3% (95% CI 92.7-98.1) and rwOS was 97.9% (95% CI 96.2-99.7).”
Title: Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study
Authors: Soraia Lobo-Martins, Veronique Debien, Elisa Agostinetto, Marianna Sirico, Giselle de Souza Carvalho, Flavia Jacobs, Chiara Molinelli, Renata Colombo Bonadio, Pedro Bergmann, Cristiano de Pádua Souza, Laura Testa, Marina Nishimuni, André João Rossi, Gabriel Kamei Guimarães, Michel Moreau, Ugo De Giorgi, José Bines, Armando Santoro, Donatienne Taylor, Francois P. Duhoux, Giacomo Barchiesi, Matteo Lambertini, Martine Piccart, Evandro de Azambuja
More posts featuring Breast Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023